Development of a radiation-activatable nanoparticle for lung cancer therapy
开发用于肺癌治疗的辐射激活纳米颗粒
基本信息
- 批准号:10259278
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-14 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgreementAntimitotic AgentsBindingBiotechnologyCanadaCancer EtiologyCancer ModelCancer cell lineCapitalCellsCisplatinCleaved cellClinicColon CarcinomaConformal RadiotherapyCoupledDNADataDevelopmentDiagnosisDoseDrug KineticsEncapsulatedEtoposideExternal Beam Radiation TherapyFailureFutureGoalsGrowthHead CancerHistopathologyIn SituIn VitroIncidenceInterruptionLabelLegal patentLicensingLigandsLipidsLungLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMethodologyMicrotubulesMusNeck CancerNeoplasm MetastasisNeurotensin ReceptorsNitric OxideNon-Small-Cell Lung CarcinomaNormal tissue morphologyOryctolagus cuniculusOxidative StressPaclitaxelPatientsPeroxonitritePersonsPhasePlatinumPositron-Emission TomographyProdrugsProductionPrognosisPropertyProteinsPulmonary InflammationRadiationRadiation therapyRadiation-Sensitizing AgentsRadioRadiosensitizationReactive Oxygen SpeciesRegional DiseaseSafetyScheduleSchemeSiteSurfaceTechnologyTestingTherapeuticTissuesToxic effectToxicity TestsTreatment EfficacyTreatment outcomeTumor SuppressionUp-Regulationacute toxicitybasebioluminescence imagingcancer therapycancer typechemoradiationchemotherapycommercial applicationcommercializationethylene glycolimprovedin vivoinhibitor/antagonistinnovationirradiationmalignant breast neoplasmmeetingsmortalitynanoparticlenanoparticle deliveryneuroendocrine differentiationnew technologypoly(lactide)preclinical studyscale upstandard caresystemic toxicitytumortumor growth
项目摘要
ABSTRACT
Non–small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality. NSCLC accounts for 85% of
all lung cancers, and is diagnosed in 234,030 persons each year in the US. For the majority of patients with
locally advanced or local regional disease, radiation therapy (RT) is the standard care. However, the dose and
efficacy of RT is limited by normal tissue toxicity. To improve tumor control, radiosensitizers such as cisplatin
and paclitaxel are used in concurrent with RT, i.e. chemoradiotherapy (CRT). However, CRT is associated with
high levels of acute and systemic toxicity. Many patients are unfit to receive CRT or complete the planned
courses. There is an urgent need of methodologies that can deliver radiosensitizers site-specifically to tumors to
enhance RT.
Athna Biotech, Inc. is developing a new CRT approach where radiation is utilized to locally activate systemically
delivered therapeutics. Specifically, we have synthesized a radiation-responsive prodrug, DM1-NO, a
nitrosylated maytansinoid DM1. The prodrug can be loaded into poly(lactide-co-glycolic)-block-poly(ethylene
glycol) nanoparticles and delivered to tumors. To improve delivery efficiency, the nanoparticles are conjugated
with NTSmut, a ligand that has high affinity towards NTSR1, which is up-regulated in 59.7% lung tumors. During
RT, irradiation elevates oxidative stress in tumors, resulting in the disassociation of DM1-NO and the release of
DM1 and nitric oxide (NO). Both DM1 and NO are effective radiosensitizers, working synergistically to enhance
RT. With nanoparticle delivery, NTSR1 targeting, conformal radiation, and radiation-responsive activation, this
approach is associated with high tumor selectivity thus permitting accurate radiosensitization. The methodology
can be extended to treatment of other cancers, such as prostate, head and neck, breast, and colon cancer,
where NTSR1 is also upregulated.
摘要
非小细胞肺癌(NSCLC)是癌症相关死亡率的主要原因。NSCLC占85%,
所有肺癌,在美国每年有234,030人被诊断出。对于大多数患有
局部晚期或局部区域性疾病,放射治疗(RT)是标准治疗。然而,剂量和
RT的功效受到正常组织毒性的限制。为了改善肿瘤控制,放射增敏剂如顺铂
和紫杉醇与RT同时使用,即化学放射疗法(CRT)。然而,CRT与
高水平的急性和全身毒性。许多患者不适合接受CRT或完成计划的治疗。
课程迫切需要能够将放射增敏剂位点特异性地递送至肿瘤的方法,
提高RT。
Athna Biotech,Inc.正在开发一种新的CRT方法,利用放射线局部激活全身
递送的治疗剂。具体来说,我们合成了一种辐射响应性前药DM 1-NO,
亚硝基化美登木素DM 1。前药可以负载到聚(丙交酯-共-乙醇酸)-嵌段-聚(乙烯)
乙二醇)纳米颗粒并递送至肿瘤。为了提高递送效率,纳米颗粒被缀合
NTSmut是一种对NTSR 1具有高亲和力的配体,NTSR 1在59.7%的肺肿瘤中上调。期间
RT,照射提高了肿瘤中的氧化应激,导致DM 1-NO的解离和DM 1-NO的释放。
DM 1和一氧化氮(NO)。DM 1和NO都是有效的放射增敏剂,协同作用以增强
RT.通过纳米颗粒递送、NTSR 1靶向、适形辐射和辐射响应激活,
该方法与高肿瘤选择性相关,因此允许精确的放射增敏。的方法
可以扩展到治疗其他癌症,如前列腺癌、头颈癌、乳腺癌和结肠癌,
其中NTSR 1也被上调。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhi Liu其他文献
Zhi Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhi Liu', 18)}}的其他基金
Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
开发用于非肌肉浸润性膀胱癌的盐基纳米药物
- 批准号:
10482565 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Inflammasome-gasdermin axis in bullous pemphigoid
大疱性类天疱疮的炎症小体-gasdermin轴
- 批准号:
10382402 - 财政年份:2018
- 资助金额:
$ 40万 - 项目类别:
Inflammasome-gasdermin axis in bullous pemphigoid
大疱性类天疱疮的炎症小体-gasdermin轴
- 批准号:
9899921 - 财政年份:2018
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Continuing Grant